Around 3.5 million patients with end-stage renal disease are on long-term dialysis each year. Image credit: Shutterstock/Davizro Photography.

The US Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) to Xeltis, green-lighting a pivotal study evaluating its haemodialysis vascular access device aXess.

The FDA nod means a US pivotal trial will soon run in parallel to an EU pivotal trial slated to recruit up to 110 patients, according to Xeltis, which has offices in both the Netherlands and US. The company did not disclose any further details about the upcoming US trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Xeltis’ chief medical officer Paulo Neves said: “This pivotal study is important in assessing and demonstrating this and marks a significant milestone in our clinical strategy in the US.”

Around 3.5 million patients with end-stage renal disease are on long-term dialysis each year. Often these patients have a fistula made to process high volumes of blood. Whilst a reliable method that improves efficiency of haemodialysis, infections with bacteria such as Staphylococcus aureus and Staphylococcus epidermidis can take hold.

Xeltis, which won €12.5m ($13.39m) in funding from the European Innovation Council in August last year, says its aXess device can help alleviate this and other complications. Designed using its endogenous tissue restoration (ETR) platform, Xeltis’ biodegradable polymer implants are gradually replaced by the patient’s own tissue. The result is a new and permanent vessel that facilitates vascular access for haemodialysis.

The vascular implant company has already reported positive 12-month data from a first-in-human European trial (NCT04898153) of the device. Out of the 20 patients enrolled, all demonstrated 100% secondary patency and 78% primary assisted patency at 12 months. The graft patency was defined as any flow through both the graft and the native vessel.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Xeltis’ CEO Eliane Schutte said: “We are very proud of the potential for aXess to transform the field of vascular access by stopping the cycle of interventions and infections and bringing our unique restorative solution to haemodialysis patients worldwide.”

The global vascular access device for the haemodialysis market is forecasted to be worth $937m in 2030, according to GlobalData analysis. The vascular access graft segment of the market is estimated to be worth $633.6m in the same period.